BACKGROUND: In patients with atrial fibrillation, left atrial appendage closure with the Watchman device prevents thromboembolism from the left atrial appendage; however, thrombus may form on the left atrial face of the device, and then potentially embolize. Herein, we studied the incidence, predictors, and clinical outcome of device-related thrombus (DRT) using a large series of clinical trial cohorts of patients undergoing Watchman implantation.
METHODS
This study included composite data from the device arm of 2 US Food and Drug Administration (FDA) randomized clinical trials and 2 FDA nonrandomized prospective registries. All studies were approved by the institutional review boards at each participating institution and all patients consented for enrollment. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. This study cohort included a total of 1739 patients that received the Watchman device (Boston Scientific Inc). All prospectively collected transesophageal echocardiography (TEE) data for these patients were reviewed for the presence or absence of DRT. The clinical characteristics and outcomes of those patients that experienced a DRT were compared with those that did not. For this analysis, procedure-related strokes were excluded.
Study Protocols
PROTECT AF (ClinicalTrials.gov. Unique identifier: NCT00 129545) and PREVAIL (ClinicalTrials.gov. Unique identifier: NCT01182441) are prospective, multicenter, randomized clinical trials that randomly assigned patients to either LAAC with the Watchman device or warfarin in a 2:1 manner. Details regarding the device, study protocol including the inclusion/ exclusion criteria, and results of these clinical trials have been previously reported. [1] [2] [3] 5, 15 In brief, the Watchman device is composed of a self-expanding nitinol frame with fixation barbs and a permeable polyester fabric. The device is available in 5 sizes (21-33 mm) and is positioned and delivered at the ostium of the left atrial appendage (LAA) via a 12F delivery sheath under fluoroscopic and TEE guidance. The postprocedural antithrombotic regimen consisted of warfarin (target international normalized ratio, 2.0-3.0) and aspirin (ASA) 81 mg daily for 45 days. Provided that the TEE at 45 days demonstrated no significant peridevice leak (<5 mm) or devicerelated thrombus, warfarin was discontinued and patients took ASA (81-325 mg) and clopidogrel 75 mg daily up to the 6-month time period. At 6 months, clopidogrel was discontinued and ASA 325 mg daily was prescribed subsequently. In the control arm, all patients remained on warfarin with a target international normalized ratio of 2.0 to 3.0.
PROTECT-AF enrolled patients with nonvalvular AF and a CHADS 2 score ≥1; left ventricular ejection fraction (LVEF) ≥30%; and without an absolute contraindication to anticoagulation with warfarin and without other potential causes of stroke besides AF (ie, atrial septal aneurysm, patent foramen ovale, aortic atheroma, and symptomatic carotid disease). 5 PREVAIL enrollment criteria were similar but modified to include patients with CHADS 2 =2 or CHADS 2 =1 if they presented at least 1 high-risk characteristic: female age ≥75 years, LVEF ≥30 but <35%, age 65 to 74 years with either diabetes mellitus or coronary artery disease, or age ≥65 years with heart failure. The study excluded patients that required chronic clopidogrel therapy for other clinical indications. 15 The maximum duration of patient follow-up was 5 years for both clinical trials. All efficacy and safety end points were independently adjudicated by an unblinded clinical events committee, and an independent data and safety monitoring board oversaw trial conduct. For the present analysis, those events that were adjudicated as procedure-related strokes were excluded.
Clinical Perspective
What Is New?
• Following percutaneous left atrial appendage closure with the Watchman device, the incidence of device-related thrombus (DRT) is 3.7% and is associated with a >3-fold higher risk of stroke and systemic embolism.
• Predictors of DRT following left atrial appendage closure are permanent history of transient ischemic attack or stroke, permanent atrial fibrillation, vascular disease, larger left atrial appendage diameter, and a lower left ventricular ejection fraction.
• DRT is not associated with an increased risk of cardiovascular or all-cause mortality.
• Nearly 75% of patients that develop DRT do not experience a stroke, and ischemic strokes occurring in patients with DRT account for ≈10% of all ischemic strokes following left atrial appendage closure.
What Are the Clinical Implications?
• Given the ramifications of DRT, a judicious surveillance strategy using periodic transesophageal echocardiography should be considered, particularly when risk factors for DRT are present.
• Anticoagulation should promptly be resumed when DRT is detected to potentially decrease the risk of subsequent ischemic stroke. 
ORIGINAL RESEARCH ARTICLE
The CAP and CAP2 (ClinicalTrials.gov. Unique identifier: NCT01760291) trials were nonrandomized prospective registries that allowed continued access to the device following the PROTECT AF and PREVAIL clinical trials, respectively. The inclusion and exclusion criteria were similar to PROTECT AF for CAP and similar to PREVAIL for CAP2. 4, 16 All events in these registries were also adjudicated by the clinical events committee. Again, procedure-related strokes were excluded from the present analysis.
DRT Assessment
In PROTECT AF and PREVAIL, TEEs were performed at 45 days, 6 months, and 12 months postimplantation. In the CAP and CAP2 registries, TEEs were performed at 45 days and 12 months. All TEEs were performed and interpreted at their respective institutions. The presence of a DRT or peridevice leak was assessed at each individual institution and was prospectively recorded. In addition, TEEs that were performed outside of study protocols were also prospectively recorded. The clinical events committee received all available source documentation and echocardiography reports and independently adjudicated all clinical events.
Statistical Analysis
Baseline characteristics were compared in subjects with versus without DRT by using a Student t test or Fisher exact test, as appropriate. Rate ratios and 95% confidence intervals (CIs) for event rates per 100 patient-years were calculated using a generalized linear mixed model with a random study effect, with the adjusted rate ratios adjusted for CHA 2 DS 2 -VASc and HAS-BLED scores in the model. DRT was modeled on baseline variables using a generalized estimating equation, accounting for correlation among subjects from the same study, with a binary distribution and a logit link function. All baseline characteristics were considered in the univariable model. If a variable was only collected in 1 study, then a univariable logistic regression model was used. Only characteristics that were collected across all studies, and that were significant in the univariable model at the P<0.1 level, were considered for the multivariable model. Backward model selection with exit criteria of 0.05 was then used to fit the final multivariable model.
RESULTS

Patient Characteristics
The patient cohort consisted of a total of 1739 patients receiving the device followed for 7159 patient-years in the 4 clinical trials: PROTECT AF n=463, PREVAIL n=269, CAP n=566, and CAP2 n=578 (see patient flow in Figure 1) . The mean age of the full cohort was 73.8±8.4 years and the mean CHA 2 DS 2 -VASc and HAS-BLED scores were 4.0±1.5 and 2.0±1.0. The patient cohort consisted of 34% women, and 28% with a history of stroke or transient ischemic attack, 90% with a history of hypertension, 46% with a history of vascular disease, and 24% with a history of congestive heart failure. The compliance for protocol-directed TEE imaging was high with 98.7%, 96.8%, and 90.9% of patients undergoing imaging at 45 days, 6 months, and 12 months, respectively.
DRT was detected in 65 (3.74%) subjects who underwent LAAC, and there were no differences in age or sex between those who experienced a DRT versus those that did not ( . Certain variables such as history of liver or renal disease, left atrium diameter, presence of spontaneous echocardiographic contrast, and LAA pulsed wave peak velocity were not uniformly collected in all the studies; however, when collected, there was no statistically significant differences between groups for these parameters (Table I in the online-only Data Supplement). There were also no discernible differences between groups with respect to device size and number of partial or full device recaptures.
Timing of DRT Detection
DRT was detected on 13 of 1706 patients (0.8%) at 45 days, 12 of 692 (1.7%) at 6 months, and 27 of 1504 (1.8%) at 12 months. Another 92 TEEs were performed outside of the protocol; of those, 21 patients (18.5%) had DRT. Only 1 patient had a DRT at implant ( Table 2 ). In an attempt to correlate DRT with the antithrombotic regimen, the annualized DRT rates were calculated for 0 to 45 days, >45 days to 6 months, >6 months to 1 year, and for any time point (Table  II in the online-only Data Supplement). Although the annualized DRT rates seem to lower with increasing time periods, the confidence intervals are wide and overlapping because of the small total patient-years of follow-up in each time period. Eight patients were observed to have a DRT detected at >1 visit; 7 subjects had 2 DRTs, and 1 subject had 3 DRTs. The timeline of DRT detection in these 8 patients with multiple DRTs is shown in Figure 2 . So in toto, there were a total of 74 DRTs that occurred in 65 subjects. Over the course ORIGINAL RESEARCH ARTICLE of the studies, there were 17 patients diagnosed with DRT by other methods than TEE, such as cardiac computed tomography.
Clinical Outcomes in Patients With DRT
During follow-up, 16 of 65 (25.0%) patients with DRT experienced an ischemic stroke or systemic embolism in comparison with 114 of 1674 (6.8%) patients without DRT (P<0.001), yielding event rates of 6.28 events/100 patient-years and 1.65 events/100 patient-years, respectively (Table 3) . This translated to an unadjusted rate ratio of 3.75 (95% CI, 2.22-6.35; P<0.001) and a CHA 2 DS 2 -VASc and HAS-BLED score adjusted rate ratio of 3.22 (95% CI, 1.90-5.45; P<0.001). As shown in Table 3 , the unadjusted and adjusted rate ratios for all stroke and systemic embolism, and ischemic stroke, as well, were similarly significantly higher for patients with DRT. Although the rate ratios for hemorrhagic stroke were also elevated for patients with DRT, it should be noted that there were only 3 events (in 2 patients) in this group. There were no differences in cardiovascular or unknown mortality and all-cause mortality between groups. Of the 142 all-cause strokes and systemic emboli, 19 occurred in patients with DRT and 123 occurred in those without DRT (P<0.001). Similarly, when looking at the 130 total ischemic strokes and systemic emboli that occurred in the entire cohort, 16 occurred in patients with DRT and 114 occurred in those without DRT (P<0.001).
Similarly, the Kaplan-Meier analyses ( Figure 3 and Figure I in the online-only Data Supplement) demonstrated that the presence of DRT was significantly associated with higher rates of ischemic stroke/systemic embolism (adjusted hazard ratio, 3.9; 95% CI, 2.3-6.8; P<0.001) and all-cause stroke/systemic embolism (adjusted hazard ratio, 4.2; 95% CI, 2.5-7.0; P<0.001). There was no difference in rates of cardiovascular mortality or all-cause mortality ( Figure II in the online-only Data Supplement).
Of the 65 patients with DRT, 17 patients (26.2%) had a total of 19 events: 13 ischemic stroke, 3 hemorrhagic strokes, and 3 system emboli. The relationship between device thrombus detection and occurrence of stroke is shown in Figure 4 . In examining the temporal relationship of event and DRT identification, 2 time window definitions were used to define causality: a time window between event and DRT identification as 1 month implied causality in 9 of 19 events (47.4%), and using a duration at 6 months increased this to 12 of 19 events (63.2%). However, there was no evidence of causality between the DRT and embolic event in 7 of 19 (36.8%) stroke/embolic events, specifically in patients 1 (second event), 3, 4, 7 (second event), 11, 13, and 14 in Figure 4 . It should be noted that 3 of these strokes (in patients 4 and 7) were hemorrhagic in nature, so the use of anticoagulation for thrombus resolution may have been partially responsible; unfortunately, medication status at the time of the event was not available.
As per the clinical trial designs, there was increased patient surveillance with 1 additional TEE at 6 months in the randomized trials that was not required in the registries. Consistent with this more aggressive surveillance strategy, there was a slightly higher rate of DRT detection after the 6-month time point, albeit not reaching statistical significance ( Figure 5A ). However, the rates of ischemic stroke or systemic embolism did not differ between these sets of clinical trials ( Figure 5B ).
Predictors of DRT
The univariable and multivariable predictors of DRT are shown in Table 4 
DISCUSSION
This study represents the largest report of DRT following LAAC with the Watchman device using prospective data from 4 FDA clinical trials: the randomized con- ever, it is important to note that the majority of patients with DRT (73.8%) did not experience a stroke/systemic embolism and the majority of strokes/systemic embolisms (86.6%) occurred in patients who never manifested a DRT; (4) there were no significant differences in mortality, either all-cause or cardiovascular/unexplained death, between the 2 groups; and (5) the presence of permanent AF, history of TIA/stroke, vascular disease, larger LAA diameter, and a lower LVEF were found to independently predict the development of DRT.
Incidence of DRT
The reported incidence of DRT following percutaneous LAAC device likely varies depending on the frequency of TEE monitoring and antithrombotic regimen used postimplantation. In our study, the presence of DRT was systematically and prospectively evaluated by TEEs performed at protocol-specific time frames following implant, 45 days and 12 months, and an additional required TEE at 6 months in the randomized trials. It is important to note that there was a high degree of compliance (>90%) with follow-up TEE evaluation. Additional TEEs performed outside of protocol requirements were also prospectively collected. Taken 
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together, the overall incidence of DRT was observed to be 3.7%, which is consistent with previously reported rates. [6] [7] [8] [9] [10] [11] [12] [13] [14] Another strength of this study is the uniform postimplantation antithrombotic regimen consisting of: dose-adjusted warfarin (target international normalized ratio, 2.0-3.0) and ASA 81 mg daily for 6 weeks, clopidogrel 75 mg and ASA 81 to 325 mg daily from 45 days to 6 months, and ASA 325 mg daily from 6 months onward. Of note, this regimen of oral anticoagulation for 6 weeks, followed by dual-antiplatelet therapy, is indeed the regimen that has been FDA approved for use with the Watchman device in the United States.
In EWOLUTION (Registry on Watchman Outcomes in Real-Life Utilization), the largest published multicenter, nonrandomized, prospective registry of Watchman implantation, the cumulative incidence of DRT was 2.6% at 3 months, 3.7% at 12 months, and 4.1% after 2 years. 11, 12, 14 But in that study, the postimplantation antithrombotic regimen was quite variable: single-or dualantiplatelet drugs were used in 67%, direct oral anticoagulants in 11%, vitamin K antagonists in 16%, and nothing in 6%. 11 Although no significant differences in DRT frequency or overall event rates were apparent between the different postimplantation antithrombotic regimens, the overall number of patients was too small to elucidate significant differences between these various regimens. In a subsequent analysis of EWOLUTION, the incidence of DRT was 4.0% after 12-months in the patients treated with dual antiplatelets postimplantation without any discernible adverse consequences of using this antithrombotic regimen. 7 Finally, in a recent multicenter, retrospective series that compared nonwarfarin oral anticoagulants with warfarin following Watchman implants, the incidence of DRT was not statistically different between groups: 0.5% with nonwarfarin oral anticoagulants and 0.9% with warfarin. 17 In addition to the postimplant antithrombotic regimen, the frequency of TEE monitoring is also likely to influence DRT detection, and hence its perceived incidence. In this study, a numerically higher rate of DRT was observed in PROTECT AF/PREVAIL than CAP/CAP2. This was likely a result of the additional TEE require- Figure 5A ). It is interesting to note that this did not translate to a discernible higher rate of ischemic stroke/systemic embolism for patients enrolled in CAP and CAP2 ( Figure 5B ). Of course, one should cautiously interpret this comparison because the overall number of DRT and stroke events in this ≈6-month window is small. Indeed, given the ramifications of DRT, our data support a reevaluation of the TEE surveillance strategy. Potential approaches include: (1) routine additional TEE surveillance at 6 months, although this would expose all patients to a considerable follow-up burden for unproven benefit; (2) an escalated TEE monitoring strategy targeted to those patients with DRT risk factors such as permanent AF, lower LVEF, history of TIA/stroke, vascular disease, and larger LAA diameter; and (3) delaying the first TEE to the ≈4-month time point (instead of 6 weeks), because DRT is most likely to manifest after oral anticoagulant discontinuation at 6 weeks, and indeed after receiving dual-antiplatelet therapy. (After FDA approval of the Watchman device, several of the authors, but not all, have used this latter approach in their routine practice.) It is important to note that none of these strategies have been rigorously compared, so these suggestions are subject to future studies.
DRT and Stroke or Systemic Embolism
In this study, we demonstrated that, in patients who develop DRT, there were increased rates of both allcause stroke/systemic embolism (RR, 3.55; P<0.001) and ischemic stroke/systemic embolism (RR, 3.22; P<0.001). The rates of hemorrhagic stroke were also increased in the patients with DRT (RR, 7.98; P=0.002). From a mechanistic perspective, it would be reasonable to speculate that patients with DRT may receive additional treatment with oral anticoagulation, thereby potentiating hemorrhagic stroke events. However, because the medication treatment that these patients received was not available for review, this remains speculation. Furthermore, the overall number of events constituting this hemorrhagic stroke end point was small, so one's confidence in this observation is diminished. Finally, despite the increased embolic event rates observed in the cohort of patients with DRT, the overall rates of both cardiovascular and all-cause mortality were not increased (RR, 1.31; P=0.486 and RR, 1.13; P=0.649, respectively). 
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In an attempt to determine whether the relationship between DRT and subsequent ischemic stroke/ systemic embolism was because of direct embolism of the DRT, or whether DRT predicted patients with high thromboembolic potential, we examined the temporal relationship between DRT and subsequent thromboembolism (Figure 4) . In the 17 patients with both DRT and stroke/embolic events either soon before or after DRT detection, a temporal relationship appears in about half the events (47%) when using a 1-month window, and increased to approximately two-thirds (63%) when the window was widened to 6 months. Three of the 5 remaining events were hemorrhagic strokes, possibly potentiated by anticoagulation treatment of the DRT. There were 8 patients that detected multiple DRTs but only 2 experienced any events (Figure 2) . This relationship between DRT and stroke/embolism stands in contrast to a previous study we published that systematically evaluated TEEs from PROTECT AF. In that study, the observed primary efficacy (stroke, systemic embolism, cardiovascular or unknown death) event rate of 3.7 per 100 patient-years for patients with DRT was intermediate between the event rates for the full Watchman (2.2 per 100 patient-years) and warfarin (3.7 per 100 patient-years) arms. 6 However, that study was limited by the small number of patients and events; indeed, there were only 3 ischemic strokes in that analysis. In contrast, a different multicenter, nonrandomized, retrospective study of LAAC (n=487) with either the Watchman device (in 58%) or Amplatzer/ Amulet devices (in 42%) suggested that DRT was associated with an increased risk of ischemic stroke or transient ischemic attack (adjusted hazard ratio, 4.39; 95% CI, 1.05-18.43; P=0.04). 18 But in that analysis, the number of patients included was relatively small, the follow-up was limited to ≈1 year, limited imaging was available, and most importantly, the postimplantation antithrombotic regimen was highly variable with only approximately one-third of patients receiving oral anticoagulants postimplantation. Nonetheless, their observation that DRT portends worsened prognosis is certainly congruent with our present data.
Timing of DRT identification is also variable in this analysis, with about half of the patients who have DRT with a positive study detected after 6 months postimplant. At that point, only single antiplatelet therapy (325 mg ASA) is recommended, and it is possible that the removal of the concomitant medications in these particular patients and slow healing exacerbates thrombus formation. In this situation, the device may become a marker rather than the cause, and these patients may be good candidates for longer durations of anticoagulation or more aggressive anticoagulation strategies to treat what could be more systemic emboli issues.
Predictors of DRT
The predictors of DRT in this study were permanent AF, history of TIA/stroke, vascular disease, larger LAA diameter, and lower LVEF. Other studies have also reported a lower LVEF, permanent AF, a history of prior thromboembolic events, and the use of larger devices to be independent predictors of DRT. 10, 13, 19 Although these are important clinical characteristics to consider, it is also important to recognize that there is no threshold level for any of these predictors that would be useful to guide clinical practice.
There are 2 interesting recent studies suggesting that deep implantation of LAAC devices may be associated with the development of DRT. 10, 19 Deep implantation may leave trabeculated portions of the LAA exposed to stagnant blood, thereby increasing the potential for A, In addition to transesophageal echocardiograms at 45 days and 12 months in CAP and CAP2 studies, the PROTECT AF and PREVAIL trials also required TEE imaging at 6 months. The additional imaging study was associated with a statistically nonsignificant increase in device-related thrombus detection. B, However, the rates of ischemic stroke or systemic embolism were not different between the studies. TEE indicates transesophageal echocardiography.
Circulation. ORIGINAL RESEARCH ARTICLE thrombus formation. However, the number of patients in these 2 studies is not large (together including <200 patients); future studies are needed with large numbers of patients and echocardiography core laboratories for objective adjudication. In addition, DRT with the Watchman device is almost invariably associated with the center of the device in the region of the exposed metal hub. Whether newer versions of this device with smaller metal hubs will result in lower rates of DRT remains to be determined.
Clinical Implications
Finally, despite the marked increased in stroke rates in patients with DRT, it is important to note that the majority of patients with DRT (73.8%) did not experience a stroke or systemic embolism. Indeed, the vast majority of events that occur in patients undergoing LAAC do not seem to be related to DRT, and other sources of emboli may be responsible for those thromboembolic events, that is, noncardioembolic stroke. Alternatively, the true incidence rates of DRT-related ischemic strokes may have been underestimated in this study because some DRTs may have completely embolized and resulted in false-negative TEEs. Furthermore, although the difference between the patient cohorts indicates a ≈3-fold increase in embolic events for patients with DRT, it is crucial to recognize that this subgroup experienced only a small proportion (≈10%) of the overall number of ischemic stroke events; and most important, the ischemic stroke rate observed in our study cohort is similar to that expected for a similar CHA 2 DS 2 -VASc cohort treated with oral anticoagulants ( Figure 6 ). 19, 20 In addition, patients choosing LAAC therapy as a stroke risk reduction option are typically not good candidates for long-term anticoagulation. Reviewing the outcomes of patients with DRT in the context of an expected rate of stroke without treatment based on risk scores, the device patients still received a 28% relative reduction in ischemic stroke rates. Certainly, DRT is associated with an increased risk of stroke, and therapeutic anticoagulation should be resumed when discovered with rigorous TEE follow-up to ensure resolution. In a single-center study, The observed ischemic stroke rate of the full 1739 patient cohort is shown, along with the fraction of these contributed by the DRT-positive and DRTnegative subgroups: 10.2% of the ischemic strokes occurred in DRT-positive patients. For comparison, the expected ischemic stroke rates if this patient cohort had been either untreated or treated with oral anticoagulation are also shown. These were calculated using published literature based on the CHA 2 DS 2 -VASc score of the cohort. In brief, the expected untreated ischemic stroke rate was determined by calculating each individual patient's yearly rate of ASA-adjusted risk and then averaging the rates for the study population; similarly, the expected ischemic stroke rate for anticoagulated patients was extrapolated by calculating the corresponding rate for a patient population with the same mean CHA 2 DS 2 -VASc score. 20, 21 ASA indicates aspirin; DRT, device-related thrombus; LAAC, left atrial appendage closure; OAC, oral anticoagulant; Pts, patients; Pt-Yrs, patient-years; and Tx, treatment.
it was shown that a short-term therapy with warfarin was able to resolve DRT in all cases. 13 
Limitations
This is a post hoc analysis of pooled data from 2 randomized controlled trials (PROTECT AF, PREVAIL) and 2 multicenter, prospective, nonrandomized registries (CAP, CAP2) and is subject to limitations inherent in such analyses. In this analysis, the presence or absence of DRT was determined by data prospectively collected and interpreted at the individual participating centers, and not by an echocardiography core laboratory. Unfortunately, source TEEs from all these patients were not available for review, and neither were antithrombotic medication therapy. Accordingly, we are unable to correlate international normalized ratio values with the presence or absence of DRT for those patients taking warfarin. The findings of this study are relevant to only the Watchman device, and may not be applicable to other LAAC closure devices. On the other hand, the general concepts raised here may be applicable to other devices. Similarly, these findings can only be applied to patients that are treated with the specific postimplantation regimen that was used in these studies. Caution should be applied when extrapolating these findings to other postimplantation antithrombotic regimens such as single-or dual-antiplatelet therapy, or the nonwarfarin oral anticoagulants. Finally, this retrospective study does not address the management of DRT; studies evaluating the use of oral anticoagulants to resolve DRT, both warfarin and nonwarfarin oral anticoagulants, are urgently required.
CONCLUSIONS
DRT occurs in ≈3.7% of patients following LAAC with the Watchman device and is associated with higher rates of all-cause stroke/systemic embolism and ischemic stroke/systemic embolism. Patients that are prone to develop DRT more commonly have permanent AF, history of TIA/stroke, vascular disease, larger LAA diameters, and lower LVEF. The majority of patients with DRT (73.8%) do not experience stroke or systemic embolism, and the majority of these events (86.6%) occur in those patients who do not have a DRT. However, when DRT is present, therapeutic anticoagulation should be promptly initiated and patients closely followed. 
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